United Therapeutics (UTHR) director sells 200 shares under 10b5-1 plan

Rhea-AI Filing Summary

UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of common stock. She sold 200 shares on February 27, 2026 at an average price of $509.55 per share under a pre-arranged Rule 10b5-1 trading plan entered into on November 24, 2025. After this transaction, she directly owns 4,845 common shares.

Insider Trade Summary

Net Seller: 200 shares ($101,910)

Net Sell 1 txn

Insider Olian Judy D.

Role Director

Sold 200 shs ($102K)

Type	Security	Shares	Price	Value
Sale	Common Stock	200	$509.55	$102K

Holdings After Transaction: Common Stock — 4,845 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Olian Judy D.

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		S(1)		200	D	$509.55	4,845	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This is a sale of common stock pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 24, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UNITED THERAPEUTICS (UTHR) report for Judy D. Olian?

UNITED THERAPEUTICS reported that director Judy D. Olian sold 200 shares of common stock. The sale occurred on February 27, 2026, as an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan.

How many UNITED THERAPEUTICS (UTHR) shares did Judy D. Olian sell and at what price?

Judy D. Olian sold 200 shares of UNITED THERAPEUTICS common stock at an average price of $509.55 per share. This was an open-market sale reported as a non-derivative transaction on the Form 4 filing.

How many UNITED THERAPEUTICS (UTHR) shares does Judy D. Olian own after this sale?

After the reported sale, Judy D. Olian directly owns 4,845 shares of UNITED THERAPEUTICS common stock. This post-transaction holding reflects her remaining direct ownership as disclosed in the Form 4 insider filing.

Was the UNITED THERAPEUTICS (UTHR) share sale by Judy D. Olian under a 10b5-1 plan?

Yes. The sale of UNITED THERAPEUTICS shares by Judy D. Olian was made under a pre-arranged Rule 10b5-1 trading plan. The plan was entered into on November 24, 2025, before the February 27, 2026 transaction.

What is the nature of Judy D. Olian’s role at UNITED THERAPEUTICS (UTHR)?

Judy D. Olian is identified as a director of UNITED THERAPEUTICS. The Form 4 filing marks her status as a board member and reports her direct ownership and the recent common stock sale transaction.

What transaction code was used for Judy D. Olian’s UNITED THERAPEUTICS (UTHR) trade?

The transaction was reported with code “S,” indicating a sale in the open market or a private transaction. It covered 200 shares of UNITED THERAPEUTICS common stock as a non-derivative open-market sale.